anti-Human TNFSF10 Antibody | anti-TNFSF10 antibody

TNFSF10 Antibody

Cat. Num. AAA8516331

• Gene Names: TNFSF10; TL2; APO2L; CD253; TRAIL; Apo-2L; TNLG6A
• Reactivity: Human
• Applications: Western Blot, Immunohistochemistry
• Purity: Immunogen affinity purified
• Synonyms: TNFSF10; TNFSF10 Antibody; APO2L; Apo-2L; CD253; TL2; TRAIL; anti-TNFSF10 antibody

• Reactivity: Human
• Specificity: TNFSF10 Antibody detects endogenous levels of total TNFSF10
• Purity/Purification: Immunogen affinity purified
• Form/Format: In phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Sequence Length: 101

• Applicable Applications for anti-TNFSF10 antibody: Western Blot (WB), Immunohistochemistry (IHC)
• Application Notes: WB: 1:500-1:2000; IHC: 1:50-1:200
• Immunogen: A synthetic peptide of human TNFSF10
• Preparation and Storage: Store at-20 degree C for 1 year

Western Blot (WB)

(Western blot analysis of extracts of placenta cell lines, using TNFSF10 antibody.)

Related Product Information for anti-TNFSF10 antibody

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1, 2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-kappaB activation (7, 9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (10-13) and DcR2 (TRAIL-R4, TRUNDD) (14-15) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (16). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (17-18).

NCBI and Uniprot Product Information

• NCBI GI #: 300193032
• NCBI GeneID: 8743
• NCBI Accession #: NP_001177871.1
• NCBI GenBank Nucleotide #: NM_001190942.1
• UniProt Accession #: P50591; A1Y9B3
• Molecular Weight: 33kDa
• NCBI Official Full Name: tumor necrosis factor ligand superfamily member 10 isoform 2
• NCBI Official Synonym Full Names: TNF superfamily member 10
• NCBI Official Symbol: TNFSF10
• NCBI Official Synonym Symbols: TL2; APO2L; CD253; TRAIL; Apo-2L; TNLG6A
• NCBI Protein Information: tumor necrosis factor ligand superfamily member 10
• UniProt Protein Name: Tumor necrosis factor ligand superfamily member 10
• Protein Family: Tumor necrosis factor ligand superfamily
• UniProt Gene Name: TNFSF10
• UniProt Synonym Gene Names: APO2L; TRAIL; Apo-2L; Protein TRAIL

NCBI Description

The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2010]

Uniprot Description

Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:26457518, PubMed:10549288). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.